Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

The information on this page is intended for news media in the European Union only.

November 15th, 2020

VIVA data presentation: Zilver® Vena™ Venous Self-Expanding Stent Demonstrates Symptom Relief in Patients

Bloomington, Ind. – At this year’s Vascular Interventional Advances (VIVA) conference, Dr. Anthony Comerota presented data on the Zilver® Vena Venous Self-Expanding Stent that demonstrates durable patency and symptom relief in patients over an extended period of time.1

Zilver Vena is a self-expanding stent designed to meet the needs of patients suffering from symptomatic iliofemoral venous outflow obstruction.1 When implanted in a patient, Zilver Vena expands to restore venous flow. 1

Zilver Vena Venous Self-Expanding Stent

At the VIVA conference, the data presented were gathered from the Zilver Vena VIVO US Study. The study involved 243 patients who were reflective of a real-world population, including representations of acute and chronic disease as well as thrombotic and non-thrombotic lesions.1 Key highlights of the study include:

“We are proud to share the Zilver VIVO data at the VIVA conference,” said Mark Breedlove, vice president of Cook Medical’s Vascular division. “We know that venous disease is a serious and complex condition. These data are a milestone in our commitment to driving venous therapies.”

For more information, visit the Zilver Vena product page here.

Dr. Comerota is a paid consultant of Cook Medical.

Please see product risk information in the IFU at

About Cook Medical
Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: our patients, our employees, and our communities. Find out more at, and for the latest news, follow us on Twitter, Facebook and LinkedIn.

1 VIVO clinical study. Web site. Published October 25, 2013. Updated April 08, 2021. Accessed April 08, 2021.